A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Subjects With Type 2 Diabetes Mellitus and Microalbuminuria
Phase of Trial: Phase II
Latest Information Update: 15 Aug 2017
At a glance
- Drugs Esaxerenone (Primary)
- Indications Diabetic nephropathies; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Inc
- 22 Sep 2016 Status changed from active, no longer recruiting to completed.
- 11 Feb 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
- 30 Jan 2015 New trial record